That’s why I Feel Comfortable With Cytokinetics Inc’s (CYTK) Future

At the time of writing, Cytokinetics Inc [CYTK] stock is trading at $73.02, up 4.15%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CYTK shares have gain 8.31% over the last week, with a monthly amount glided 1.08%, and seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

On 1, April 2024, Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference. In a post published today on Yahoo Finance, Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 2:15 PM Eastern Time.

From an analyst’s perspective:

Cytokinetics Inc [NASDAQ: CYTK] stock has seen the most recent analyst activity on January 24, 2024, when UBS downgraded its rating to a Neutral and also boosted its price target to $92 from $61. Previously, Morgan Stanley downgraded its rating to Equal-Weight on January 05, 2024, and elevated its price target to $90. On November 09, 2023, Goldman initiated with a Buy rating and assigned a price target of $50 on the stock. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $66 on November 07, 2023. SVB Securities initiated its recommendation with a Outperform and recommended $58 as its price target on August 15, 2023. BofA Securities started tracking with a Neutral rating for this stock on February 17, 2023, and assigned it a price target of $49. In a note dated December 23, 2022, Needham reiterated an Buy rating on this stock and revised its target price from $60 to $58.

For the past year, the stock price of Cytokinetics Inc fluctuated between $25.98 and $110.25. Currently, Wall Street analysts expect the stock to reach $60.71 within the next 12 months. Cytokinetics Inc [NASDAQ: CYTK] shares were valued at $73.02 at the most recent close of the market. An investor can expect a potential drop of -16.86% based on the average CYTK price forecast.

Analyzing the CYTK fundamentals

According to Cytokinetics Inc [NASDAQ:CYTK], the company’s sales were 7.53M for trailing twelve months, which represents an -14.56% plunge. Gross Profit Margin for this corporation currently stands at -32.4% with Operating Profit Margin at -65.9%, Pretax Profit Margin comes in at -69.89%, and Net Profit Margin reading is -69.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.64, Equity is 1.51 and Total Capital is -0.69. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.64.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 70.23 points at the first support level, and at 67.43 for the second support level. However, for the 1st resistance point, the stock is sitting at 74.49, and for the 2nd resistance point, it is at 75.95.

Cytokinetics Inc [CYTK] reported earnings per share of -$1.38 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.97/share, meaning a difference of -$0.41 and a surprise factor of -42.30%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.35 per share as compared to estimates of -$0.74 per share, a difference of -$0.61 representing a surprise of -82.40%.

Ratios To Look Out For

It is important to note that Cytokinetics Inc [NASDAQ:CYTK] has a current ratio of 6.12. Further, the Quick Ratio stands at 6.12, while the Cash Ratio is 1.1. Considering the valuation of this stock, the price to sales ratio is 998.81.

Transactions by insiders

Recent insider trading involved Malik Fady Ibraham, EVP Research & Development, that happened on Mar 05 ’24 when 32604.0 shares were sold. Director, HENDERSON JOHN T completed a deal on Feb 14 ’24 to sell 5000.0 shares. Meanwhile, President & CEO Blum Robert I sold 12500.0 shares on Feb 13 ’24.

Related Posts